PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

LiveStream: Paradigm Biopharma (ASX:PAR) pursuing FDA review, page-15

  1. 287 Posts.
    lightbulb Created with Sketch. 39
    yes but they have always wanted the best deal and that will materialize once the potential partners are happy that their decision will be a wise investment....... that is once the fda approve p3 ....once they have approved it things will hot up and we all get a better value for the company.......
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.